CG Invites Co., Ltd.

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The company is also involved in the development of Ivaltinostat, an anti-cancer drug, currently under phase 2 stage for the treatment of pancreatic cancer and myelodysplastic syndrome, as well as preclinical stage for the treatment of acute myeloid leukemia and hepatocellular carcinoma; Camrelizumab, an anti-cancer drug, currently under phase 3 stage for the treatment of NSCLC; and Luxeptinib, an anti-cancer drug, currently under phase 1 stage for the treatment of acute myeloid leukemia, chronic lymphocytic leukemia, and non-hodgkin’s lymphoma. In addition, it engages in the development of Nilofabicin, anti-infective drug, currently under phas 1 stage for the treatment of MRSA infection; and Ivaltinostat, currently under phase 1 stage for the treatment of fibrotic and metabolic diseases, such as fibrosis. The company was formerly known as CrystalGenomics Invites Co., LTD. and changed its name to CG Invites Co., Ltd. in April 2024. CG Invites Co., Ltd. was incorporated in 2000 and is headquartered in Seoul, South Korea.